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Roberta A. Jong, MDa
aDepartment of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
bDepartment of Medical Imaging, Edith Wolfson Medical Center, Holon, Israel
cDepartment of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, CanadaAbstractObjectives: To compare the underestimation of ductal carcinoma in situ (DCIS) vs DCIS with ‘‘possible invasion’’ at breast biopsy and to
determine if any factors related to clinical indication, imaging abnormality, biopsy, or DCIS-grade affected the likelihood of underestimation.
Methods: Of 3836 consecutive lesions that were biopsied by using a 14-gauge needle, 117 lesions revealed DCIS. Surgical pathology results
of invasive carcinoma were compared with needle biopsy results of DCIS or DCIS with possible invasion. Clinical indication, imaging
abnormality, biopsy guidance modality, sample number, and histologic grade were recorded. Yates corrected c2 and Fisher exact tests were
used to determine differences between groups.
Results: A total of 101 lesions were DCIS and 16 were DCIS with possible invasion at biopsy. Thirty-six of 117 lesions (31%) revealed
invasive carcinoma at resection pathology. Invasive carcinoma was present more often when DCIS with possible invasion was diagnosed
compared with pure DCIS (7/16 [44%] vs 29/101 [29%], P ¼ .36). No factor, including clinical indication, imaging abnormality, biopsy
guidance method, sample number, or grade, was found to significantly affect the likelihood of underestimation for lesions diagnosed as DCIS
vs DCIS with ‘‘possible invasion.’’ The likelihood of pure DCIS underestimation significantly increased when lesions were high grade
compared with either intermediate or low grade (18/44 [41%] vs 9/44 [21%] vs 2/10 [20%], P ¼ .03).
Conclusion: For lesions biopsied by using a 14-gauge needle, there is a trend towards underestimation of the presence of invasive carcinoma
when pathology reveals DCIS with possible invasion compared with pure DCIS. High-grade DCIS was significantly more likely to be
underestimated.ResumeObjectifs : Comparer le taux de sous-estimation des carcinomes canalaires in situ (CCIS) par rapport a celui des CCIS avec « invasion
possible » lors des biopsies du sein et determiner si tout facteur se rapportant aux indications cliniques, a des anomalies relatives a l’imagerie,
a la biopsie ou au grade du CCIS avait une incidence sur la probabilite de sous-estimation.
Methodes : Sur 3 836 lesions consecutives biopsiees au moyen d’une aiguille de calibre 14, 117 lesions correspondaient a des CCIS. On
a compare les resultats pathologiques chirurgicaux des carcinomes invasifs avec ceux des biopsies a l’aiguille des CCIS ou des CCIS avec
invasion possible. On a consigne les indications cliniques, les anomalies relatives a l’imagerie, les lignes directrices en matiere de biopsie, le
numero d’echantillon et le grade histologique. On a utilise la correction de Yates au calcul du chi carre (c2) et la methode exacte de Fisher
pour determiner les differences entre les groupes.
Resultats : Au total, 101 lesions correspondaient a des CCIS et 16 a des CCIS avec invasion possible selon les resultats de la biopsie. Trente-
six des 117 lesions (31 %) comportaient un carcinome invasif lors de l’examen pathologique de resection. Les carcinomes invasifs etaient
plus frequents dans le cas d’un diagnostic de CCIS avec invasion possible que dans celui d’un diagnostic de CCIS pur (7/16 [44 %] par
rapport a 29/101 [29 %], P ¼ 0,36). Les facteurs comme les indications cliniques, les anomalies relatives a l’imagerie, les lignes directrices
en matiere de biopsie, le numero d’echantillon ou le grade histologique n’avait une incidence considerable sur la probabilite de sous-
estimation des lesions ayant fait l’objet d’un diagnostic de CCIS pur, comparativement aux diagnostics de CCIS avec « invasion possible ».* Address for correspondence: Arazi-Kleinman, MD, Department of Medical Imaging, Edith Wolfson Medical Center, 62 HaLohamim Street, PO Box 5,
Holon 58100 Israel.
E-mail address: t_arazikleinman@yahoo.com (T. Arazi-Kleinman).
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147DCIS vs DCIS with ‘‘possible invasion’’ / Canadian Association of Radiologists Journal 63 (2012) 146e152La probabilite de sous-estimation des CCIS etait beaucoup plus elevee dans le cas de lesions de haut grade que dans le cas de lesions de grade
intermediaire ou de bas grade (18/44 [41 %] par rapport a 9/44 [21 %] et 2/10 [20 %], P ¼ 0,03).
Conclusion : En ce qui concerne les lesions biopsiees au moyen d’une aiguille de calibre 14, la tendance a la sous-estimation de la presence
de carcinomes invasifs est superieure lorsque l’examen pathologique permet de deceler un CCIS avec invasion possible, comparativement a
un CCIS pur. Les CCIS de haut grade etaient beaucoup plus sujets a la sous-estimation.
 2012 Canadian Association of Radiologists. All rights reserved.
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Histologic underestimation occurs when percutaneous
breast needle biopsy reveals pure ductal carcinoma in situ
(DCIS), and upon subsequent excision of the same lesion,
invasive cancer is diagnosed. This scenario likely occurs
because of undersampling of a lesion that contains both
DCIS and invasive components. Patient management is
compromised when DCIS underestimation occurs on percu-
taneous biopsy and is not diagnosed until final surgical
pathology results are available, because a second operation,
not routinely performed for noninvasive cancer, is then
required to stage the axillary lymph nodes [1].
At pathology, percutaneous breast biopsy specimens are
reported as ‘‘DCIS with possible invasion’’ or ‘‘at least
DCIS,’’ when the stromal epithelial interface is not demon-
strable (ie, when dissociated malignant cells are noted),
whenever the suspicious invasive focus does not appear at the
plane of deeper sections or immunohistochemistry cases are
not resolvable. By using a 9-gauge vacuum-assisted biopsy
(VAB) device under magnetic resonance imaging (MRI)
guidance, Lee et al [2] reported an 81% underestimation rate
for lesions diagnosed as DCIS with possible invasion,
compared with a 17% rate for pure DCIS lesions, and is the
factor with the greatest affect on reported underestimation
rates.
The remaining underestimation rate data available come
from stereotactic- and ultrasound-guided biopsy literature
[3e10]. Because DCIS traditionally is detected by
mammographic calcifications, the underestimation rate
literature is predominantly based on stereotactic-guided
breast biopsy. At stereotactic biopsy, the reported DCIS
underestimation rates range between 10%e36%, increasing
when the biopsy was performed by using a 14-gauge core vs
an 11-gauge VAB needle (20% vs 11%, P < .001), when the
target lesion was a mass vs calcifications (24% vs 12%,
P < .001), and when fewer than 10 samples were retrieved
(18% vs 12%, P < .02) [4,9].
When using ultrasound as guidance for 11- or 14-gauge
percutaneous needle biopsy, Lee et al [6] reported DCIS
underestimation in nearly 42% of cases. Underestimation
rates were higher for palpable lesions (60%) and for lesions
with correlated mass seen on mammography (55%).
The impact of biopsy pathology yielding DCIS with
possible invasion on the surgical outcome has not been
previously reported for stereotactic- or ultrasound-guided
breast biopsies by using a 14-gauge needle. The aims ofthis study were to compare the frequencies of histologic
underestimation of invasive breast carcinoma that occurs
when percutaneous breast biopsy performed by using an
automated 14-gauge needle revealed pure DCIS vs DCIS
with possible invasion, according to the clinical indication
for imaging, imaging abnormality, biopsy guidance method,
number of samples obtained, and DCIS pathologic grade.
Materials and Methods
With institutional review board approval, a retrospective
review was performed of 3836 consecutive lesions that
underwent image-guided percutaneous breast biopsy in our
medical imaging department over a period of 4 years
(September 2003 until August 2007). Inclusion criteria for
the study were the following: biopsy performed by using an
automated 14-gauge needle; diagnosis of DCIS or DCIS with
possible invasion, without the presence of invasive cancer; no
synchronous lesion in the same breast diagnosed as invasive
cancer; and the lesion surgically excised, with surgical
pathology reviewed at our institution. Clinical, imaging, and
pathology findings were reviewed.
We identified 117 consecutive lesions that met our
inclusion criteria, 36 lesions (31%) revealed invasive cancer
at subsequent resection pathology, 77 lesions (66%) revealed
DCIS, and 4 lesions (3%) were benign (with no residual
DCIS) at subsequent resection pathology. Eighty of 117
lesions (68%) presented as mammographic calcifications, 20
of 117 (17%) were mass only, and 17 of 117 (15%) were
a mass with calcifications.Biopsy MethodLesions were biopsied according to the best method of
imaging visualization for guidance. Calcifications were
biopsied under stereotactic guidance, and masses or hypo-
echoic areas that were detected by ultrasound were sampled
by using ultrasound guidance. If a mass is suspected based
on mammographic findings, then the usual practice at our
institution is to perform an ultrasound (ie, a mammographic
mass or asymmetry or concerning calcifications in dense
breast tissue).
In our practice, almost all lesions are biopsied with a 14-
gauge needle by using ultrasound guidance and most by
using stereotactic guidance. The 14-gauge needle biopsies
under stereotactic guidance are performed on a dedicated
table (stereoGuide; Lorad, Danbury, CT), with digital spot
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(Manan Promag biopsy gun [Manan Medical Products Inc,
Wheeling, IL] or Bard MAGNUM Reusable core biopsy
instrument [Bard Biopsy Systems Inc, Tempe, AZ]).
Ultrasound-guided breast biopsies are also performed by
using the same 14-gauge automated spring-loaded devices
and imaged by using a linear 5-12 MHz transducer (HDI
5000; Philips Healthcare Inc, Andover, MA). Biopsies were
performed or supervised by 1 of 6 radiologists who
specialize in breast imaging. All biopsies performed by
trainees were directly supervised by an attending specialist.
The biopsy accuracy was confirmed by the attending radi-
ologist who was supervising the biopsy and observing in the
room. If any question remained regarding sampling, then our
practice was for the attending physician to perform addi-
tional passes during the biopsy. All attending radiologists had
prior experience in breast imaging and percutaneous
biopsies.Pathology Methods and DefinitionsPathology reports of percutaneous breast biopsies and
surgical specimens were reviewed. At the time of diagnosis,
all specimens were signed out by a group of 5 pathologists
with a focused practice in the area of breast pathology. Cases
were classified as DCIS when malignant proliferation was
contained within the basement membrane of native ducts or
lobules and surrounded by myoepithelial cells [11]. Nuclear
grade was determined by using the Holland classification
[12]. When nuclear grade was low, cases were classified as:
low-grade DCIS, only when the neoplastic proliferation
replaced the entire duct; and atypical ductal hyperplasia,
when there was incomplete involvement of the duct by cells
indistinguishable from low-grade DCIS [12,13]. DCIS with
microinvasion was defined as tumour cells, singly or in
clusters, infiltrating the periductal stroma, or occasionally as
a projection of neoplastic cells through a disrupted basement
membrane in continuity with the DCIS, measuring equal to
or less than 1 mm in greatest dimension [12]. Foci of stromal
invasion tend to be accompanied by a desmoplastic reaction
characterized by scattered chronic inflammatory cells
arranged with pale staining loose arrays of new collagen.
Definitive diagnosis of stromal invasion may be difficult,
and serial sections and immunohistochemical studies with
myoepithelial markers are used in these cases [14,15].
However, when the stromal epithelial interface is not
demonstrable (ie, when dissociated malignant cells are
noted), or whenever the suspicious invasive focus does not
appear at the plane of deeper sections or immunohisto-
chemistry cases are not resolvable, these equivocal cases
were reported as ‘‘DCIS with possible invasion’’ or ‘‘at least
DCIS’’ (refer to Figure 1). Invasive carcinoma was reported
whenever there were unequivocal features of stromal inva-
sion. A DCIS underestimation was defined as a lesion that
yielded DCIS without frank microinvasion or invasion at
percutaneous breast biopsy, and with microinvasion or
invasive cancer at the resection pathology.All tissue samples were routinely fixed in 4% neutral
buffered formalin and embedded in paraffin. Up to 3 cores
were embedded in each block, and at least 2 hematoxylin and
eosinestained slides were obtained for microscopic evalua-
tion. Additional sections and special stains were ordered at
the pathologist’s discretion. Excisional biopsy specimens
were oriented by the surgeon, and the margins were inked by
the pathologist. Specimens were serially sectioned. In
general, lumpectomies that could fit in 30 blocks were
entirely submitted, and larger specimens were sampled based
on specimen radiography and gross abnormalities.Data Collection and AnalysisData collected for this study was as follows: indication for
initial breast imaging, including routine screening; high-risk
screening (BRCA1 or 2 mutation carriers, family history or
prior personal history of breast cancer, prior mantle radia-
tion, and risk markers on prior biopsy); clinical finding
(palpable mass, pain, or nipple symptoms [discharge, inver-
sion, Paget disease]); patient age, breast side, and lesion
location; biopsy date; imaging abnormality (calcifications or
mass with or without calcifications); biopsy imaging guid-
ance method; the number of samples obtained; and DCIS
pathologic grading of the biopsy specimen and the resection
pathology.
Data were entered into a computerized spreadsheet (Excel;
Microsoft Corporation, Redmond, WA). The likelihood of
DCIS underestimation was calculated separately for each
biopsy method, imaging abnormality, number of samples
obtained per lesion, DCIS grade as determined on the core
biopsy, and indication for initial breast imaging. Tests for
statistical significance were performed with computerized
statistical software by using the Yates corrected c2 and Fisher
exact tests, with P< .05 considered significant [16]. The 95%
confidence intervals were calculated by using the exact bino-
mial and Poisson distributions [17].
Results
One hundred and seventeen lesions in 109 women were
identified with a diagnosis of DCIS on percutaneous biopsy
and subsequently underwent surgical excision with resection
pathology reviewed at our institution. The mean age of the
patients was 57 years (range, 33e84 years). The lesions were
found in 112 breasts (59 left and 53 right breasts). Three
patients had bilateral lesions, and 5 patients had biopsies of
different lesions in the same breast.
Of 117 lesions, 101 were DCIS vs 16 DCIS with possible
invasion at percutaneous biopsy performed by using an
automated 14-gauge needle. Most (77/117 [66%]) of the
lesions yielded pure DCIS at the resection pathology, fol-
lowed by 36 (31%) which revealed invasive cancer, and 4
lesions (3%) yielded benign tissue. The likelihood of DCIS
underestimation was higher for the lesions that yielded DCIS
with possible invasion vs DCIS on biopsy pathology (44% vs
29%, P ¼ .36). Refer to Table 1 for final excisional pathology
Figure 1. Mammographic and pathologic findings in a 65-year-old woman with prior right mastectomy. (A) Left mediolateral oblique and (B) Craniocaudate
views demonstrate a new cluster of microcalcifications in the central upper left breast, without an associated mass (circle). (C) Lateral and (D) caudocranial
spot compression magnification views characterize the calcifications as pleomorphic. (E) Low-power photomicrograph (hematoxylin and eosin stain), showing
high-grade ductal carcinoma in situ (DCIS), solid type (arrow heads), diagnosed by stereotactic 14-gauge core needle biopsy. A small group of malignant cells
are noted in the stroma (arrow) and appear to lack myoepithelial cells at its periphery (high-power photomicrograph insert). This focus does not appear on
a deeper level, thus, immunohistochemistry to demonstrate the lack of myoepithelial cells and confirm stromal invasion is not feasible in this case. As a result,
the lesion was designated as DCIS with possible invasion. Subsequent resection yielded a focus of 1 cm of invasive ductal carcinoma. This figure is available in
colour online at http://carjonline.org/.
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invasion on percutaneous biopsy.
The most frequent indication for imaging was routine
screening (48/117 [41%]), followed by a history of breast
cancer (37/117 [32%]), a clinical finding (20/117 [17%]),
and screening of patients with high risk for breast cancer (12/
117 [10%]). Patients with a mutation in the BRCA 1 or 2
gene or with a family history suggestive of hereditary breast
cancer were considered high risk for breast cancer. See Table
2 for the underestimation rates of lesions diagnosed as DCIS
with or without possible invasion according to clinical
indication for lesion detection. Although there was no
statistical difference in underestimation rates between lesionsdiagnosed as pure DCIS vs DCIS with possible invasion
according to clinical indication for lesion detection, there
was a trend towards a higher likelihood of underestimation
DCIS with possible invasion when lesions presented as
a clinical finding (3/6 [50%] vs 5/14 [36%], P ¼ .9) and in
patients with a history of breast cancer (3/7 [43%] vs 5/30
[17%], P ¼ .3).
Most lesions were biopsied by using stereotactic guidance
(80/117 [68%]), and the remainder were biopsied by using
ultrasound guidance (37/117 [32%]). The final surgical
pathology results in lesions that yielded DCIS or DCIS with
possible invasion at core biopsy according to the biopsy
guidance method are listed in Table 1. Due to the fact that all
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stereotactic guidance and that all masses were biopsied using
ultrasound guidance regardless if they were associated with
calcifications or not, the results according to method of
biopsy guidance (stereotactic or ultrasound) and the imaging
abnormality (calcifications or mass) are equivalent. Although
underestimation rates were not significantly different for
pure DCIS compared with DCIS with possible invasion
according to the presenting imaging abnormality or method
of guidance used for biopsy, there was a trend for lesions
presenting as calcifications, biopsied under stereotactic
guidance to be underestimated when the biopsy yielded
DCIS with possible invasion compared with pure DCIS (3/6
[50%] vs. 18/74 [74%], P ¼ .4). There was a trend to a higher
likelihood of pure DCIS underestimation when the lesion
presented as a mass or when the biopsy was performed under
ultrasound guidance compared with the lesion presenting as
calcifications or biopsied under stereotactic guidance (11/27
[41%] vs 18/74 [24%], P ¼ .17).
The number of samples taken at a biopsy ranged from
3-14 cores, with an average of 6 samples. Six or fewer
samples were taken during the biopsy of most lesions
(97/117 [83%]). Underestimation rates according to the
number of samples taken and DCIS lesion type on initial
core biopsy are shown in Table 1. Although the results were
not statistically significant, there was a trend towards
increased underestimation for lesions that yielded DCIS with
possible invasion compared with pure DCIS when 6 or fewer
samples were obtained (7/15 [47%] vs 25/82 [31%], P ¼ .4).
Most lesions that yielded pure DCIS on the biopsy spec-
imen were either high grade (44/101 [43.5%]) or intermediate
grade (44/101 [43.5%]) followed by low grade (10/101
[10%]). Grading was not available for 3 biopsy specimens
(3/101 [3%]). Although there was no statistical difference
between the groups of pure DCIS vs DCIS with possible
invasion according to nuclear grade, the likelihood of under-
estimation was significantly higher for the pure DCIS group
when the nuclear grade was high (41%) compared with inter-
mediate (21%) and low grade (20%), P ¼ .03. See Table 2 for
underestimation rates according to DCIS nuclear grade.
The size of the invasive component in the 36 lesions that
yielded invasive carcinoma at surgery was known in 35
(97%) and ranged between microinvasion (less than 1 mm) to
4.0 cm, with an average of 0.63 cm. The invasive component
was greater or equal to 1 cm but less than 5 cm (pT1c or pT2)
for 25% of lesions (9/36), less than 1 cm but greater than
1 mm (pT1a or pT1b) for 50% of lesions (18/36), and less
than 1 mm (pTmic) for 22% of lesions (8/36).
Discussion
DCIS underestimation on percutaneous breast biopsy
compromises a patient’s surgical management, because it
necessitates a second surgery, not routinely performed for
DCIS lesions, to assess the axillary lymph nodes. The effect
of ‘‘possible invasion’’ being present when DCIS is diag-
nosed on 14-gauge needle biopsy performed by using
Table 2
Likelihood of invasion at surgery in lesions that yield pure DCIS vs DCIS with possible invasion at core biopsy according to method of biopsy guidance,
number of samples, clinical indication, and nuclear grade
Factor
DCIS (N ¼ 101)
DCIS with possible
microinvasion (N ¼ 16)
P Total no. (%)
No. invasive
surgery/no. lesions %
No. invasive
surgery/no. lesions %
Modality
Stereotactic biopsy 18/74 24 3/6 50 .4 80 (68)
Ultrasound biopsy 11/27 41 4/10 40 NA 37 (32)
No. cores
6 25/82 31 7/15 47 .4 97 (83)
>6 4/19 21 0/1 NA .6 20 (17)
Indication
Routine screening 16/45 36 1/3 33 NA 48 (41)
High-risk screeninga 3/12 25 0 NA NA 12 (10)
History of breast cancer 5/30 17 3/7 43 .3 37 (32)
Clinical finding 5/14 36 3/6 50 .9 20 (17)
DCIS grade
Unknown 0/3 NA 2/2 100 NA 5 (4)
Low 2/10 20 1/1 100 NA 11 (10)
Intermediate 9/44 21 1/3 33 NA 47 (40)
High 18/44 41 3/10 30 .8 54 (46)
Total 29/101 29 7/16 44 .4
DCIS ¼ ductal carcinoma in situ; NA ¼ not applicable.
aBRCA1, BRCA2, family history, prior mantle radiation.
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has not been previously reported. In our study of 117 lesions
that yielded DCIS at percutaneous breast biopsy performed
by using an automated 14-gauge needle, the likelihood of
invasive disease at surgery tended to be higher when the
lesions revealed DCIS with possible invasion, compared with
lesions that yielded pure DCIS (44% vs 29%, P ¼ .36).
Our findings of a 44% underestimation rate for DCIS with
possible invasion diagnosed by using a 14-gauge needle
under stereotactic or ultrasound guidance is much lower than
the 80% previously reported when using a 9-gauge VAB
under MRI guidance [2]. The higher underestimation rate,
despite obtaining a much greater volume of tissue when
using a 9-gauge VAB device compared with a 14-gauge tru-
cut needle, although counterintuitive, is most likely
explained by the differences in lesion types visualized and
targeted with MRI compared with either ultrasound or
mammography. Because tumors detected when using MRI
are visible based on biological activity related to lesion
enhancement, this may be a more relevant indicator of the
propensity of invasion compared with nonphysiologic
imaging with mammography and ultrasound.
The overall underestimation for the study group was 31%
(36/117), which is in the range reported in the literature
(10%e42%) [3e10]. Our data demonstrated a statistically
significant increase in the likelihood of invasive cancer at
subsequent surgery for pure DCIS lesions with a high nuclear
grade compared with intermediate- and low-grade lesions
(18/44 [41%] vs 9/44 [21%] vs 2/10 [20%], P ¼ .03). Our
results are comparable with those of previous studies, finding
one of the most consistent predictors of invasive disease to be
high-grade DCIS, as reported underestimation rates for high-
grade DCIS at 14-gauge core or 11-gauge VAB range from13%e36% compared with 7%e13% for low- or intermediate-
grade DCIS [18,19]. Small numbers in the subgroup of DCIS
with ‘‘possible invasion’’ preclude statistical comparison
between groups based on nuclear grade.
There was a trend towards pure DCIS lesions having
a higher likelihood of underestimation when the lesion pre-
sented as a mass and was biopsied by using ultrasound
compared with stereotactic guidance (11/27 [41%] vs 18/74
[24%], P ¼ .17). Our findings support previously reported
higher rates of DCIS underestimation for lesions biopsied
under ultrasound compared with stereotactic guidance
(36.5%e42% vs 10%e36%, respectively) [3e10]. No
additional factors, including imaging abnormality, clinical
indication for imaging, or number of samples, were found to
have a statistically significant effect on underestimation rates
of DCIS on 14-gauge core biopsy.
Four initial DCIS lesions yielded benign results in the
final surgical specimen, including 1 radial scar, 2 normal
breast tissue, and 1 fibrocystic change. In all cases, the
biopsy site reaction was identified, and none of the DCIS
lesions were low grade, therefore, the event of an initial
false-positive pathology reading was very low. The likely
explanation was that either the lesions were completely
removed by the core needle biopsy procedure, or that the
residual disease was so minute that it could not be demon-
strated at the level of histopathologic sections, including the
previous biopsy site.
This study is limited because it was performed at a single
centre, with a relatively small number of biopsy specimens
that yielded DCIS with ‘‘possible invasion’’ and hence does
not have the power for significant statistics. Although some
of the biopsies were performed by trainees, all biopsies were
supervised by experienced breast radiologists who routinely
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a sufficient volume of lesional tissue. This factor, therefore,
likely has little effect on the results, as supported by the
similar underestimation rates reported in the literature.
In summary, lesions biopsied by using a 14-gauge needle
under stereotactic or ultrasound guidance tended to under-
estimate the presence of invasive cancer when pathology
revealed DCIS with possible invasion compared with pure
DCIS, as surgical pathology revealed invasive disease in 44%
of lesions that yielded DCIS with possible invasion
compared with 29% of lesions that yielded pure DCIS. High
nuclear grade significantly increased the likelihood of pure
DCIS lesion histologic underestimation. Whereas DCIS is
recognized as a heterogeneous disease whose biology
remains elusive, the literature continues to evolve that
identifies high-risk factors for DCIS. Although controversial,
with the growing body of literature, there is a push to
consider sentinel lymph node biopsy at the time of initial
definitive lumpectomy for patients with high-risk DCIS to
decrease the morbidity and cost associated with a second
operation after invasive cancer is found [20]. Our results
support recommendations by other researchers that high-
grade DCIS is considered a high-risk factor and lymph-
node sampling by sentinel node procedure may be
appropriate at the first operation. The additional factor of
‘‘possible invasion’’ associated with DCIS at 14-gauge core
biopsy could be considered a high-risk marker and be given
similar considerations for sentinel lymph node sampling at
the initial lumpectomy but requires further investigation.References
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